Biodegradable poly(ε-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen

International Journal of Pharmaceutics

Volumn 249, Issue 1-2, 2002, Pages 127-138

  Chawla, Jugminder S ^a   Amiji, Mansoor M ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

MCF 7 cells; Nanoparticles; Poly( caprolactone); Tamoxifen; Targeted delivery system

Indexed keywords

BACTERIAL PROTEIN; BUFFER; DODECYL SULFATE SODIUM; NANOPARTICLE; PHOSPHATE; POLOXAMER; POLYCAPROLACTONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SODIUM CHLORIDE; TAMOXIFEN; TRIACYLGLYCEROL LIPASE; AQUAPLAST, CAPROLACTONE; POLYESTER;

ARTICLE; BIODEGRADATION; CELL LINE; CHEMICAL PROCEDURES; CHEMISTRY; CONTROLLED STUDY; COULTER COUNTER; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG POTENTIATION; DRUG RELEASE; DRUG TARGETING; DRUG UPTAKE; ENDOCYTOSIS; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; PARTICLE SIZE; PRIORITY JOURNAL; PSEUDOMONAS; SCANNING ELECTRON MICROSCOPY; SOLVENT DISPLACEMENT METHOD; ZETA POTENTIAL; BIODEGRADABLE IMPLANT; CELL CULTURE; DRUG EFFECT; METABOLISM; METHODOLOGY; NANOTECHNOLOGY;

ABSORBABLE IMPLANTS; DRUG DELIVERY SYSTEMS; HUMANS; NANOTECHNOLOGY; POLYESTERS; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0037027882     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(02)00483-0     Document Type: Article

References (28)

1. Brigger I., Chaminade P., Marsaud V., Appel M., Besnard M., Gurny R., Renoir M., Couvreur P. Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation. Int. J. Pharm. 214:2001;37-42.
2. Burtis C.A., Ashwood E.R. Tietz Fundamentals of Clinical Chemistry. fourth ed. 1996;803 W.B. Saunders and Company, Philadelphia, PA.
3. Chen J., Ma A., Lai Y., Chen Y., Cui M. The mechanism of degradation for the absorbable biomaterials poly(ε-caprolactone) in vitro and in vivo. J. Biomed. Eng. 14:(4):1997;334-337.
4. Chen D.R., Bei J.Z., Wang S.G. Polycaprolactone microparticles and their biodegradation. Polym. Degrad. Stab. 67:2000;455-459.
5. Cohen S., Yoshioka T., Lucarelli M., Hwang L.H., Langer R. Controlled delivery system for proteins based on poly(lactic/glycolic acid) microspheres. Pharm. Res. 8:1991;713-720.
6. Dellian M., Yuan F., Trubetosky V.S., Torchillin V.P., Jain R.K. Vascular permeability in a human tumor xenograft: molecular charge dependence. Br. J. Cancer. 82:2000;1513-1518.
7. Espuelas M.S., Legrand P., Irache J.M., Gamazo C., Orecchioni A.M., Devissaguet J.P., Ygartua P. Poly(ε-caprolactone) nanospheres as an alternative way to reduce amphotericin-B toxicity. Int. J. Pharm. 158:1997;19-27.
8. Folkman J. Fighting cancer by attacking its blood supply. Sci. Am. 275:1996;150-154.
9. Gan Z., Yu D., Zhong Z., Liang Q., Jing X. Enzymatic degradation of poly(ε-caprolactone)/poly(DL-lactide) blends in phosphate buffer solution. Polymer. 40:1999;2859-2862.
10. Ge H., Hu S., Yang S., Jiang X., Yang C. Preparation, characterization and drug release behaviors of drug loaded ε-caprolactone/L-lactide copolymer nanoparticles. J. Appl. Polym. Sci. 75:2000;874-882.
11. Huang X., Brazel C.S. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J. Control. Release. 73:2001;121-136.
12. Jain R.K. Barriers to drug delivery in solid tumors. Sci. Am. 271:1994;58-65.
13. Johnston S.R. Acquired tamoxifen resistance in human breast cancer-potential mechanisms and clinical implications. Anticancer Drugs. 8:1997;911-930.
14. Jordan V.C. The strategic use of antiestrogens to control the development and growth of breast cancer. Cancer. 70:(Suppl. 4):1992;977-982.
15. Jordan V.C. Designer estrogens. Sci. Am. 279:1998;60-67.
16. Jordan V.C. Targeted antiestrogens to prevent breast cancer. Trends Endocrinol. Metab. 10:1999;312-317.
17. Lerner L.J., Jordan V.C. Development of antiestrogens and their use in breast cancer: eighth cain memorial award lecture. Cancer Res. 50:1990;4177-4189.
18. MacCallum J., Cummings J., Dixon J.M., Miller W.R. Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in plasma. J. Chromatogr. 678:1996;317-323.
19. Macgregor J.I., Jordan V.C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 50:1998;151-196.
20. Maeda D., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release. 65:2000;271-284.
21. Muller R.H., Mader K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 50:2000;161-177.
22. Munster P.N., Hudis C.A. Adjuvant therapy for resectable breast-cancer. Hematol. Oncol. Clin. North Am. 13:1999;391-413.
23. Osborne C.K., Fuqua S.A. Mechanisms of tamoxifen resistance. Breast Cancer Res. Treat. 32:1994;49-55.
24. Pitt C.G. Poly(ε-caprolactone) and its copolymers. Langer R., Chasin M., Bioderadable Polymers as Drug Delivery Systems. 1990;71-120 Marcel Decker Inc, New York, NY.
25. Ponsart S., Coudane J., Vert M. A novel route to poly(ε-caprolactone) based copolymers via anionic derivatization. Biomacromolecules. 1:2000;275-281.
26. Rich J., Kortesuo P., Ahola M., Yli-Urpo A., Kiesvaara J., Seppala J. Effect of molecular weight of poly(e-caprolactone-co-lactide) on toremifine citrate release from copolymer/silica xerogel composites. Int. J. Pharm. 212:2001;121-130.
27. Wu C., Jim T.F., Gan Z., Zhao Y., Wang S. A heterogeneous catalytic kinetics for enzymatic biodegradation of poly(ε-caprolactone) nanoparticles in aqueous solution. Polymer. 41:2000;3593-3597.
28. Zhihua G., Fung J.T., Jing X., Wu C., Kuliche W.K. A novel laser light-scattering study of enzymatic biodegradation of poly(ε-caprolactone) nanoparticles. Polymer. 40:1999;1961-1967.